Global incidence and mortality for prostate cancer: analysis of temporal patterns and trends in 36 countries, Eur Urol, vol.70, pp.862-874, 2016. ,
Rising prostate-specific antigen after primary prostate cancer therapy, Nat Clin Pract Urol, vol.2, pp.174-182, 2005. ,
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent, Eur Urol, vol.71, pp.618-629, 2016. ,
New clinical indications for (18) F/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature, Eur Urol, vol.70, pp.161-175, 2016. ,
Evaluation of hybrid (6)(8) Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy, J Nucl Med, vol.56, pp.668-674, 2015. ,
Novel preclinical and radiopharmaceutical aspects of [(68)Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer, Pharmaceuticals, vol.7, pp.779-796, 2014. ,
68Ga-PSMA PET/CT: joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0, Eur J Nucl Med Mol Imaging, vol.44, pp.1014-1024, 2017. ,
Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-cholinebased PET/CT for the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, vol.41, pp.11-20, 2014. ,
Prospective comparison of 18F-fluoromethylcholine versus 68Ga-PSMA PET/CT in prostate cancer patients who have rising psa after curative treatment and are being considered for targeted therapy, J Nucl Med, vol.56, pp.1185-1190, 2015. ,
68Ga-PSMA-PET/CT in patients with biochemical prostate cancer recurrence and negative 18FCholine-PET/CT, Clin Nucl Med, vol.41, pp.515-521, 2016. ,
TEP/TDM et récidive biologique d'adénocarcinome prostatique: apport du 68 Ga-PSMA-11 lorsque la 18 F-fluorocholine n'est pas contributive, Prog Urol, vol.27, pp.474-481, 2017. ,
Impact of 68 Ga-PSMA PET on the management of patients with prostate cancer: a systematic review and meta-analysis, Eur Urol, vol.74, pp.179-190, 2018. ,
Oligometastatic prostate cancer: definitions, clinical outcomes and treatment considerations, Nat Rev Urol, vol.14, pp.15-25, 2017. ,
Recommandations en oncourologie 2016-2018 du CCAFU: cancer de la prostate, Prog En Urol, vol.27, pp.95-143, 2016. ,
DOI : 10.1016/s1166-7087(16)30705-9
,
Immunohistochemical validation of PSMA expression measured by 68Ga-PSMA PET/CT in primary prostate cancer, J Nucl Med, vol.59, pp.238-243, 2018. ,
Correlación entre el volumen molecular tumoral evaluado con PET/TC con 68 Ga-PSMA y los niveles de antígeno prostático específico, Rev Esp Med Nucl E Imagen Mol, vol.37, pp.223-228, 2018. ,
Antibody-based therapeutics: focus on prostate cancer, Cancer Metastasis Rev, vol.24, pp.521-537, 2005. ,
Positron-emission tomography imaging in urological oncology: current aspects and developments, Int J Urol, 2018. ,
68Ga-PSMA-11 PET-CT study in prostate cancer patients with biochemical recurrence and non-contributive 18F-Choline PET-CT: Impact on therapeutic decision-making and biomarker changes, The Prostate, pp.1-8, 2018. ,
URL : https://hal.archives-ouvertes.fr/inserm-01980821
,